PRA

WuXi PharmaTech, PRA form joint venture for Chinese market

Thursday, December 20, 2012 10:32 AM

CRO WuXi PharmaTech, with operations in China and the U.S., and CRO PRA have signed a joint venture agreement to offer a broad platform of phase I-IV clinical trial services in China, Hong Kong and Macau, including clinical trial monitoring, project management, regulatory strategy and submissions, data management, biostatistics, drug safety reporting and medical monitoring.

More... »

PRA expands operations in China

Wednesday, August 22, 2012 01:10 PM

PRA, a global CRO, has opened a second office in China to accommodate its expansion in China and the Asia Pacific region.

More... »

Prevention trial studies population 100% genetically predisposed to early-onset Alzheimer’s

Monday, August 6, 2012 07:00 AM

For the first time ever, an experimental drug is being tested to determine whether it can prevent Alzheimer’s disease in a population that has a 100% genetic predisposition for early onset of the disease. The study, to start next year, will be one of only a few being conducted to test prevention treatments for a genetically predestined disease.

More... »

PRA participates in landmark Alzheimer’s prevention trial

Thursday, July 26, 2012 09:52 AM

PRA, a global CRO, is participating in an Alzheimer’s disease study that could lead to treatments delaying or even preventing the emergence of symptoms in people destined to develop the disease because of their genetic background.

More... »

Cetero sold to investor group, renamed PRACS Institute

Wednesday, June 20, 2012 02:38 PM

Cary, N.C.-based Cetero Research has finalized the sale of the company to its investor group, led by Freeport Financial, following the company’s Chapter 11 bankruptcy filing court approval of the sale.

More... »

PRA expands operations in the Netherlands and U.K.

Monday, May 21, 2012 03:48 PM

PRA, a global CRO, is expanding its operations in the Netherlands and the U.K. to accommodate staff growth and strong client demand for its phase IIa-IIIb service offerings.

More... »

PRA, Amgen collaborate on biosimilar development program

Wednesday, May 2, 2012 09:18 AM

PRA, a global CRO, has formed a strategic relationship with biotech Amgen for a series of phase III studies to develop several biosimilar drugs on a worldwide basis.

More... »

Susan Stansfield named executive VP, clinical development at Premier Research

Friday, January 13, 2012 12:03 PM

Premier Research Group has named Susan C. Stansfield, Ph.D., its new executive vice president of clinical development.

More... »

UCB inks strategic partnerships with Parexel, PRA

Monday, November 28, 2011 08:00 AM

The sponsor-CRO strategic partnerships just keep coming. 

More... »

UCB enters strategic partnerships with Parexel and PRA

Thursday, November 17, 2011 10:33 AM

Brussels, Belgium-based UCB has entered into strategic partnerships with Parexel and PRA to drive UCB’s operational clinical development activities. The agreements are effective for all of UCB’s new clinical study programs on a global basis.

More... »